electroCore, Inc. (ECOR) Company Overview

electroCore, Inc. is a Nasdaq Capital Market-listed bioelectronic technology company that commercializes non-invasive neuromodulation. Its principal medical products are gammaCore for primary headache conditions and Quell Fibromyalgia for adults with fibromyalgia and high pain sensitivity. Truvaga serves consumer wellness, while TAC-STIM targets human performance. The official product portfolio shows how a shared stimulation platform is adapted across prescription, consumer and government markets.

Which products and customers define the business?

Where does electroCore operate?

The United States is the economic center: FY2025 U.S. product revenue was $30.1 million, versus $1.7 million in the United Kingdom, $0.2 million in other markets and $0.1 million of Japan license revenue. Overseas sales use electroCore U.K. and distributors, while direct German operations are paused. The FY2025 Form 10-K therefore describes a primarily U.S. commercialization story with selective international extensions.

electroCore sells devices and consumables through commercial channels rather than reporting formal operating segments. U.S. prescription revenue comes mainly from gammaCore and Quell sales to healthcare channels, especially the Department of Veterans Affairs. General Wellness revenue comes from Truvaga ecommerce and selected partners. Outside-U.S., TAC-STIM and in-license revenue are smaller contributors.

What is the channel economics chain?

Why does customer concentration matter?

The VA accounted for 74.8% of Q1 2026 net sales, up from 70.3% in Q1 2025. That concentration is simultaneously electroCore’s strongest distribution advantage and its largest commercial dependency. The company had reached 200 VA facilities by March 31, 2026, versus 175 one year earlier, and approximately 15,000 VA patients had received a gammaCore device. Yet management estimated penetration at only about 2.5% of the addressable VA headache market. The model therefore has room to expand within an established account system, but changes in federal purchasing, contract access, clinical adoption or distributor performance could affect a large share of revenue.

For the quarter ended March 31, 2026, net sales reached a record $9.6 million versus $6.7 million a year earlier. Growth came from VA prescription demand, acquired Quell sales and Truvaga. The official Q1 2026 earnings release reaffirmed approximately 30% FY2026 revenue-growth guidance over FY2025.

Which latest-period figures matter most?

Is operating leverage beginning to appear?

Adjusted EBITDA loss improved 24% year over year to $2.3 million, while GAAP net loss widened because of transition charges. Truvaga generated about $1.5 million, up 38%, with 2.37x return on advertising spend; Quell exceeded $1.0 million for the quarter. These are encouraging growth signals, but the Q1 2026 Form 10-Q still shows a material operating deficit and dependence on external capital.

electroCore’s history is a progression from one therapeutic technology to a broader portfolio and channel strategy. Each turning point changed its market, regulation, customer base or funding needs.

From nVNS breakthrough to portfolio expansion

1. 2005
   electroCore was founded to develop neuromodulation technologies, establishing the scientific and intellectual-property base behind today’s portfolio.
2. 2010
   The company achieved a technical breakthrough in delivering vagus nerve stimulation non-invasively through the skin of the neck, removing the need for an implanted lead and pulse generator.
3. 2017
   The FDA cleared gammaCore for acute episodic cluster-headache pain, validating the first commercial medical application of the platform.
4. 2019
   gammaCore became available through the U.S. Federal Supply Schedule, creating the government-channel pathway that now produces most company revenue.
5. 2022
   electroCore launched the Truvaga wellness brand and TAC-STIM initiative, moving beyond prescription headache treatment into direct-to-consumer wellness and human performance.
6. 2024
   The app-enabled Truvaga Plus and next-generation TAC-STIM were commercially launched, increasing software dependence and marketing intensity.
7. 2025
   The NeuroMetrix acquisition added Quell Fibromyalgia, a mobile application and a health-cloud platform, diversifying the prescription portfolio and deepening the VA opportunity.
8. 2026
   Truvaga entered the United Kingdom, Quell Relief was prepared for launch, and a leadership transition placed CFO Joshua Lev in the Interim President role.

The 2010 breakthrough is described on electroCore’s official nVNS technology page. Non-invasive delivery reduces procedural friction versus implanted stimulation, while medical indications still require evidence, clearance and reimbursement.

The 2024 launch of Truvaga Plus and the 2025 NeuroMetrix acquisition expanded the opportunity set while adding consumer-acquisition, integration, software and inventory risks.

Why do the technology and patent portfolio matter?

electroCore’s primary resource advantage is proprietary electrical stimulation delivered non-invasively through the neck. At December 31, 2025, it reported 170 issued U.S. patents, 39 U.S. applications and 80 international patents and applications, with issued patents expiring from 2026 through 2039. The portfolio can slow imitation, although rivals can challenge claims, design around them or use different pathways.

How does the government channel strengthen the model?

Commercial access is the second advantage. The Federal Supply Schedule contract runs through June 14, 2030, and Lovell Government Services supports FSS, GSA, DAPA and ECAT procurement. This infrastructure is difficult for a new entrant to recreate quickly. The trade-off is concentration: the same channel represented roughly three-quarters of Q1 2026 sales.

For MBA-style analysis, electroCore’s valuable resources are proprietary nVNS know-how, regulatory clearances, clinical evidence and federal access. The resources are difficult to replicate, but the company has not yet proven that they can produce self-funded growth. That distinction separates a technological advantage from a fully durable economic moat.

Competition spans pharmaceuticals, medical devices and wellness alternatives. The FY2025 filing names Cefaly, Nerivio and SAVI Dual among neuromodulation rivals. gammaCore must win on clinical evidence, access, convenience, cost and treatment profile—not merely prove that stimulation works.

Which rivals pressure prescription neuromodulation?

What changes in consumer wellness?

Truvaga competes in a less protected market against wearables, meditation applications and wellness products backed by larger marketing ecosystems. TAC-STIM’s commercial launch targeted human performance, but revenue was $0.4 million in FY2025, down from $1.2 million in FY2024. Product differentiation therefore does not guarantee stable demand.

What do profitability and cash burn show?

FY2025 revenue rose 27% to $32.0 million and gross profit reached $27.8 million, an 87% margin. Yet R&D was $2.7 million and SG&A was $38.2 million, producing a $13.2 million operating loss, a $14.0 million net loss and $8.2 million of operating cash use. Strong product margins have not yet covered commercialization and corporate costs.

How much liquidity and financing risk exists?

Management and the auditor identified substantial doubt about continued operations because forecast cash was insufficient for at least twelve months from statement issuance. electroCore can use its shelf registration and at-the-market facility, but financing creates dilution. Revenue growth and lower cash burn must improve before capital becomes too expensive or restrictive.

The definitive proxy filed July 20, 2026 reported 9.0 million shares outstanding on July 10, with one vote per share. Although there is no dual-class structure, several holders have meaningful influence. It also describes a six-member classified board, all determined independent under Nasdaq and SEC standards.

Which shareholders have meaningful influence?

What do leadership and board structure signal?

Separate chairman and principal executive roles support oversight, while the classified board can slow a change in control. Execution during the CEO search is the immediate issue: Daniel Goldberger retired effective April 1, 2026, and the company recorded substantial transition costs. Selecting a permanent chief executive is therefore an operating variable, not only a governance matter.

Where could growth come from?

What could weaken the story?

Which KPIs belong in a DCF model?

A DCF model should separate VA prescription growth, Quell adoption, Truvaga customer economics and supporting costs. Near-term value depends on SG&A growth relative to gross profit; terminal value depends on whether electroCore becomes self-funded. Debt, dilution, patent life, litigation and clinical spending should be modeled explicitly rather than buried in a generic discount rate.

electroCore is trying to turn non-invasive nerve stimulation into a multi-product platform. FDA-cleared products, patents, high gross margins, VA adoption, federal access and Quell support the strategy. Q1 2026 revenue growth of 43% and a smaller adjusted EBITDA loss indicate operating leverage is possible.

The counterweight is financial. electroCore remains unprofitable, used $3.0 million of operating cash in Q1 2026, held $8.8 million of cash and securities at March 31, carried secured debt and disclosed going-concern doubt. Concentration, reimbursement, consumer economics, litigation and leadership transition make durable free cash flow uncertain.

What should be monitored next?

• Quarterly net sales versus management’s approximately 30% FY2026 growth objective.
• VA facilities, patient penetration and the VA share of revenue.
• Quell Fibromyalgia sales and the commercial launch of Quell Relief.
• Truvaga revenue, ROAS and evidence of repeat or recurring consumer economics.
• Gross margin, adjusted EBITDA loss and operating cash use.
• Cash runway, ATM issuance, debt compliance and changes in share count.
• Resolution of the lease-accounting material weakness and legal proceedings.
• Appointment of a permanent chief executive and execution under the new commercial leadership team.